scholarly journals Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma

2020 ◽  
Vol 10 ◽  
Author(s):  
Yankang Cui ◽  
Chenkui Miao ◽  
Chao Hou ◽  
Zengjun Wang ◽  
Bianjiang Liu
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Prognostic Biomarker ◽  
Cell Renal Cell Carcinoma

scholarly journals MP92-02 EVALUATION OF TUMOR PD-1 EXPRESSION AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH LOCALIZED CLEAR CELL RENAL CELL CARCINOMA

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Kyu Kim ◽  
Rishi Sekar ◽  
Michelle DiMarco ◽  
Dattatraya Patil ◽  
Adeboye Osunkoya ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Prognostic Biomarker ◽  
Cell Renal Cell Carcinoma

scholarly journals PPARα gene is a diagnostic and prognostic biomarker in clear cell renal cell carcinoma by integrated bioinformatics analysis

2019 ◽  
Vol 10 (10) ◽  
pp. 2319-2331
Author(s):  
Yongwen Luo ◽  
Liang Chen ◽  
Gang Wang ◽  
Guofeng Qian ◽  
Xuefeng Liu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Bioinformatics Analysis ◽  
Clear Cell ◽  
Prognostic Biomarker ◽  
Cell Renal Cell Carcinoma

Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target

2018 ◽  
Vol 56 (1) ◽  
pp. 43-49 ◽  
Author(s):  
Dongming Chen ◽  
Wei Chen ◽  
Yong Xu ◽  
Meng Zhu ◽  
Yi Xiao ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Prognostic Biomarker ◽  
Transcriptional Regulatory Network ◽  
Human Endogenous Retrovirus ◽  
Molecular Evidence ◽  
Cell Renal Cell Carcinoma

BackgroundClear cell renal cell carcinoma (ccRCC) is a malignant urogenital cancer with high mortality; however, current progress in understanding its molecular mechanism and predicting clinical treatment outcome is limited. Therefore, this study is to evaluate the clinical significance of immune inhibitory molecular human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) in ccRCC prognosis and transcriptional regulatory network.MethodsExpression ofHHLA2in ccRCC was examined by an online database platform ONCOMINE. The ONCOMINE result was independently validated by qRT-PCR and immunohistochemistry. Kaplan-Meier survival was generated using IBM SPSS Statistics V.22. ccRCC tissues cells with high HHLA2 were sorted and subjected to microarray transcriptional profiling and analysis.ResultsIt was shown that expression of HHLA2 was statistically significantly increased in ccRCC tissues compared with normal renal tissues at both transcriptional and protein level. Moreover, the expression of HHLA2 was closely correlated with multiple clinicopathological features including tumour size, clinical stage and histological grade. High HHLA2 expression was associated with poor overall survival and clinical outcome. Comprehensive microarray analysis further identified thousands of HHLA2 targets including mRNA, long non-coding RNA and circular RNA that might function in various biological processes, especially, immune response.ConclusionIncreased HHLA2 expression was observed in ccRCC tumour tissue, which leads to a remarkable shorter overall survival and poorer prognosis. Together with other molecular evidence, we have demonstrated that HHLA2 could be a potential prognostic biomarker for ccRCC.

CLDN10 associated with immune infiltration is a novel prognostic biomarker for clear cell renal cell carcinoma

Epigenomics ◽  
2020 ◽  
Author(s):  
Wuping Yang ◽  
Lei Li ◽  
Kenan Zhang ◽  
Kaifang Ma ◽  
Yanqing Gong ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Prognostic Biomarker ◽  
Clinicopathological Characteristics ◽  
Dna Hypermethylation ◽  
Cell Renal Cell Carcinoma ◽  
Using Data ◽  
Cox Analysis

Aims: To identify the clinical roles of CLDN10 in clear cell renal cell carcinoma (ccRCC). Materials & methods: Using data from TCGA-KIRC, GEO DataSets and laboratory experiments to determine the prognostic and clinicopathological characteristics of CLDN10. Results: CLDN10 expression was remarkably reduced in ccRCC. Downregulated CLDN10 was related to metastasis and poor prognosis. Multivariate Cox analysis determined that elevated CLDN10 expression was independently correlated with longer OS and DFS. Moreover, CLDN10 expression was negatively associated with the methylation levels of cg10305311 and cg16275739. CLDN10 expression was also associated with naive CD4 and memory T-cell and dendritic cell infiltration. Conclusions: Immune-related CLDN10 is an independent prognostic biomarker of ccRCC. DNA hypermethylation plays an important role in decreased CLDN10 expression.

Sign in / Sign up

Export Citation Format

Share Document